Small noncoding RNAs (sncRNAs), including miRNAs, piRNAs and snoRNAs, can provide further biological insights into the mechanisms of chronic kidney disease (CKD) in diabetes. Researchers from Leiden University Medical Center and collaborating institutions previously discovered that various classes of circulating sncRNAs are associated with kidney function (eGFR, uACR) and prevalent diabetic CKD.
Diabetic kidney disease (DKD) is the most prevalent long-term complication of diabetes, affecting up to 30% of individuals with type 1 diabetes within the first 10 years of diagnosis.
Diabetic kidney disease (DKD) is a chronic complication of type 1 and type 2 diabetes with albuminuria and progressive kidney failure; about 20%-40% of patients with diabetes will develop some type of kidney disease.
Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted at 40 sites across China, the 2-Succeed phase II trial is designed to evaluate the efficacy and safety of SC-0062 in patients with chronic kidney disease with proteinuria.
Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II diabetic kidney disease cohort. Conducted at 40 sites across China, the 2-Succeed phase II trial is designed to evaluate the efficacy and safety of SC-0062 in patients with chronic kidney disease with proteinuria.
About four months after varoglutamstat failed in Alzheimer’s disease, Vivoryon Therapeutics NV disclosed data from the Viviad phase IIb study with the same compound in kidney disease that provided cause for hope – and Anne Doering, chief financial officer, said the new data “reinforce our strategic shift.”
OTU deubiquitinase 5 (OTUD5) is a deubiquitinating enzyme that has been shown to play a key role in mediating innate immunity and inflammation development, and which is also involved in various cancers.
Biocity Biopharmaceutics Co. Ltd.’s selective endothelin receptor type A antagonist, SC-0062, met the primary endpoint of reducing proteinuria in a phase II chronic kidney disease trial. The candidate showed a clinically meaningful and statistically significant reduction in proteinuria, with a clear dose-response relationship and good safety profile.
Previous studies have demonstrated that CaMKKβ/AMPK signaling plays an important role in regulating mitochondrial homeostasis and that down-regulation of CaMKKβ could contribute to the pathogenesis of diabetic kidney disease (DKD).
Diabetic retinopathy and diabetic kidney disease are frequent microvascular complications of diabetes, both related to exacerbated vascular permeability coming from microvascular barrier malfunctioning.
